Breaking News Bar

Business News and Information

Breakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma

NEW YORK, October 18, 2017 /PRNewswire/ --

If you want a Stock Review on BCRX, CELG, JUNO, or LXRX then come over to and sign up for your free customized report. Research reports have been issued by today on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Celgene Corp. (NASDAQ: CELG), Juno Therapeutics Inc. (NASDAQ: JUNO), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). These companies operate in the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges, from expanding crop sizes to treating disease. Daily Stock Tracker published free research reports on these stocks today at:

BioCryst Pharmaceuticals 

Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s shares declined 0.59%, closing Tuesday's trading session at $5.08. The stock recorded a trading volume of 556,365 shares. Shares of the Company are trading 1.78% above their 50-day moving average. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have a Relative Strength Index (RSI) of 50.24.

On September 21st, 2017, BioCryst Pharma announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application for RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor, extending its availability for the treatment of acute uncomplicated influenza to pediatric patients two years and older who have been symptomatic for no more than two days. The pediatric approval was based on the interim analysis of an ongoing pediatric clinical study. See our free and comprehensive research report on BCRX at:


On Tuesday, shares in Summit, New Jersey headquartered Celgene Corp. recorded a trading volume of 4.29 million shares, which was above their three months average volume of 3.64 million shares. The stock rose 1.57%, ending the day at $138.86. The Company's shares have advanced 2.86% in the previous three months and 19.97% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.65% and 9.41%, respectively. Furthermore, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have an RSI of 48.52.

On October 02nd, 2017, Celgene announced that it will host a conference call and live audio webcast on October 26th, 2017 at 9:00 a.m. ET to discuss Q3 2017 financial and operational results. The webcast can be accessed under the Investor Relations page of the Company's website.

On October 17th, 2017, research firm Bernstein initiated an 'Outperform' rating on the Company's stock. CELG free research report is just a click away at:

Juno Therapeutics 

Seattle, Washington headquartered Juno Therapeutics Inc.'s stock finished the day 0.37% higher at $43.04 with a total trading volume of 2.37 million shares. The Company's shares have surged 52.46% in the previous three months and 128.33% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.06% and 55.55%, respectively. Additionally, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have an RSI of 57.18.

On September 26th, 2017, Juno Therapeutics announced the closing of its follow-on public offering of 7,015,000 shares of its common stock at a price to the public of $41.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase up to an additional 915,000 shares of common stock.

On October 09th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $34 a share to $56 a share. Sign up for your complimentary report on JUNO at:

Lexicon Pharmaceuticals 

Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. ended yesterday's session 0.53% lower at $11.23. The stock recorded a trading volume of 379,183 shares. The Company's shares are trading 16.16% below their 50-day moving average. Moreover, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 32.12.

On September 27th, 2017, Lexicon Pharma announced that it has initiated dosing in a Phase-1 study of LX9211, an orally-administered small molecule for the treatment of neuropathic pain. LX9211 is a selective inhibitor of AAK1 (adapter-associated kinase), which in preclinical studies demonstrated significant reduction in pain response in a series of pain models and was well-tolerated at and above efficacious doses in animals. Register for free on and download the latest research report on LXRX at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear